Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125923 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1AOC3EPHX1 | |
| SCHEMBL11552641 | 0.88 | LMNA (0.52) | LMNAKDM4EL3MBTL1AOC3EPHX1 | |
| SCHEMBL1838937 | 0.86 | ESR1 (0.50) | LMNAKDM4EL3MBTL1SLC6A2CYP1A2 | |
| SCHEMBL29152730 | 0.86 | TAAR1 (0.54) | KDM4E | |
| SCHEMBL25343509 | 0.84 | SMO (0.53) | LMNAKDM4EL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL8145964 | 0.84 | LMNA (0.48) | LMNAKDM4EL3MBTL1AOC3EPHX1 | |
| SCHEMBL4058254 | 0.84 | PPARG (0.49) | LMNAKDM4EL3MBTL1AOC3SLC6A2 | |
| SCHEMBL8352649 | 0.84 | SOAT1 (0.53) | LMNAKDM4EL3MBTL1AOC3EPHX1 | |
| SCHEMBL12982418 | 0.84 | MAOB (0.50) | AOC3EPHX1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13232184 | 0.84 | TRPA1 (0.50) | LMNAKDM4ESLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613220-A | Method for synthesizing chiral alcohol compound by hydrogenolysis and asymmetric synthesis of palladium-catalyzed epoxy compound | 中国科学院大连化学物理研究所 | 2025-03-14 | — | — | CN | disclosed |
| CN-108250042-A | (S)-(-) preparation method of -1,1,2- triphenyls -1,2- ethylene glycol | 常州沃腾化工科技有限公司 | 2018-07-06 | — | — | CN | disclosed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | disclosed |
| WO-2010008729-A2 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | KANEKA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1942103-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Kaneka Corporation (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7109345-B1 | Efficient and convenient procedure for the synthesis of B-alkylated oxazaborolidines derived from ephedrine and norephedrine | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-19 | — | — | US | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
| US-5306844-A | Tartaric acid amide derivative and method of producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0298695-B1 | TARTARIC ACID AMIDE DERIVATIVE AND METHOD OF PRODUCING THE SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1993-05-12 | — | — | EP | disclosed |
| EP-0298695-A2 | Tartaric acid amide derivative and method of producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | LMNA 3711/4885KDM4E 4873/4885L3MBTL1 2414/4885 |
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | SMS, SRM, ABHD5 | LMNA 3742/4885KDM4E 1801/4885L3MBTL1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.